Immunogenicity and safety of Papilloguard® 4, the first quadrivalent HPV vaccine combined with adjuvant system 04, versus Gardasil® in healthy 15-25-year-old individuals: a phase III, randomized, double-blind, non-inferiority trial.
- DOI
- 10.1016/j.vaccine.2026.128886
- Published
- 2026 Aug 13
- Container
- Vaccine
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.vaccine.2026.128886,
title = {Immunogenicity and safety of Papilloguard® 4, the first quadrivalent HPV vaccine combined with adjuvant system 04, versus Gardasil® in healthy 15-25-year-old individuals: a phase III, randomized, double-blind, non-inferiority trial.},
author = {Mardani M and Darazam IA and Moini A and Ebrahimi A and Mirhassani R and Barati S and Shahpari R and Modiri G and Fallah N and Albooyeh S and Neyshaburinezhad N and Karimi-Zarchi M and Kashanian M and Sabzvari A and Kafi H},
year = {2026},
journal = {Vaccine},
doi = {10.1016/j.vaccine.2026.128886},
url = {https://doi.org/10.1016/j.vaccine.2026.128886}
}RIS
TY - JOUR TI - Immunogenicity and safety of Papilloguard® 4, the first quadrivalent HPV vaccine combined with adjuvant system 04, versus Gardasil® in healthy 15-25-year-old individuals: a phase III, randomized, double-blind, non-inferiority trial. AU - Mardani M AU - Darazam IA AU - Moini A AU - Ebrahimi A AU - Mirhassani R AU - Barati S AU - Shahpari R AU - Modiri G AU - Fallah N AU - Albooyeh S AU - Neyshaburinezhad N AU - Karimi-Zarchi M AU - Kashanian M AU - Sabzvari A AU - Kafi H PY - 2026 JO - Vaccine DO - 10.1016/j.vaccine.2026.128886 UR - https://doi.org/10.1016/j.vaccine.2026.128886 ER -
APA
M, M., IA, D., A, M., A, E., R, M., S, B., R, S., G, M., N, F., S, A., N, N., M, K., M, K., A, S., & H, K. (2026). Immunogenicity and safety of Papilloguard® 4, the first quadrivalent HPV vaccine combined with adjuvant system 04, versus Gardasil® in healthy 15-25-year-old individuals: a phase III, randomized, double-blind, non-inferiority trial.. Vaccine. https://doi.org/10.1016/j.vaccine.2026.128886
Source records
- pubmed · retrieved 2026-09-26T01:10:12.242Z